Entos Pharmaceuticals Inc.
Developer of nucleic acid therapeutics delivery technologies based on a fusion protein-mediated viral–lipid hybrid platform. Activities described on the site include platform R&D, plasmid DNA vaccine development (early-phase clinical evaluation), formulation and scale-up work, GMP manufacturing operations, preclinical in vivo research, assay development, and partnership activity.
Industries
Nr. of Employees
small (1-50)
Entos Pharmaceuticals Inc.
Unit 4550, 10230 Jasper Avenue, Edmonton, AB, T5J 4P6, Canada (Global headquarters)
Patents
Products
Fusion protein-mediated viral–lipid hybrid delivery platform (nucleic acid delivery)
A delivery platform that uses fusion proteins and viral–lipid hybrid particles to enable direct membrane fusion delivery of nucleic acid payloads with the goal of achieving targeted biodistribution and redosable dosing.
Plasmid DNA COVID-19 booster vaccine candidate (fridge-stable pDNA formulation)
A plasmid DNA vaccine booster candidate formulated for refrigerated stability that is being evaluated in an early-phase clinical trial; described advantages include strong T-cell responses and lower cold-chain requirements compared with some existing vaccines.
Fusion protein-mediated viral–lipid hybrid delivery platform (nucleic acid delivery)
A delivery platform that uses fusion proteins and viral–lipid hybrid particles to enable direct membrane fusion delivery of nucleic acid payloads with the goal of achieving targeted biodistribution and redosable dosing.
Plasmid DNA COVID-19 booster vaccine candidate (fridge-stable pDNA formulation)
A plasmid DNA vaccine booster candidate formulated for refrigerated stability that is being evaluated in an early-phase clinical trial; described advantages include strong T-cell responses and lower cold-chain requirements compared with some existing vaccines.
Expertise Areas
- Genetic medicine delivery systems
- Nucleic acid vaccine development (pDNA)
- Biomanufacturing and CMC
- Formulation development and stability
Key Technologies
- Plasmid DNA (pDNA) vaccines
- Fusion protein-mediated viral–lipid hybrid delivery
- Lipid nanoparticle formulations
- AI-based biodistribution targeting
News & Updates
Announcement of a partnership to accelerate biomanufacturing of next-generation therapeutics.
Reported partnership and funding with the governments of Canada and Alberta to support biomanufacturing of next-generation therapeutics.
Listed on the company's news pages as an award/recognition.
Announcement of a partnership to accelerate biomanufacturing of next-generation therapeutics.
Reported partnership and funding with the governments of Canada and Alberta to support biomanufacturing of next-generation therapeutics.
Listed on the company's news pages as an award/recognition.